Here are three things to know:
1. MagnetOs Putty received FDA 510(k) clearance in August 2017 as an autograft extender in the posterolateral spine.
2. While MagnetOs Putty must be used with autograft as a bone graft extender in the posterolateral spine, it is intended for standalone use in the extremities and pelvis.
3. MagnetOs Putty is intended to fill bony voids or skeletal system gaps. It is designed to resorb and be replaced with bone during the healing process.
More articles on biologics:
5 things to know about Carmell Therapeutics
Global spinal biologics market to exceed $2.36B by 2021: 3 findings
Anika Therapeutics resumes distribution of cartilage regeneration treatments
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
